Company ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
2.38 ^USD	+5.87%		-2.62%	-43.02%

Jul. 03	Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
Jul. 02	Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	MT

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Number of employees: 35

USD in Million	2022	Weight	2023	Weight	Delta
Cancer Novel Drugs 100.0 %	0	nan %	12	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	-	-	12	100.0 %	-

Managers	Title	Age	Since
Carl Firth FOU	Founder	51	09-12-31
Kiran Asarpota DFI	Director of Finance/CFO	45	10-10-31
Alexandre Kaoukhov CTO	Chief Tech/Sci/R&D Officer	-	22-03-14
Stephen Doyle PRN	Corporate Officer/Principal	50	18-01-31
Ben Goodger LAW	General Counsel	61	16-10-31

Members of the board	Title	Age	Since
Robert Hoffman BRD	Director/Board Member	58	18-10-29
Andrew Howden CHM	Chairman	64	16-03-31
Carl Firth FOU	Founder	51	09-12-31
Kathleen Metters BRD	Director/Board Member	66	21-03-17
Neil Graham BRD	Director/Board Member	65	21-02-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	337,297,360	333,924,386 ( 99.00 %)	0	99.00 %

Name	Equities	%	Valuation
BVF, Inc. 4.641 %	1,049,999	4.641 %	450 450 $
Velan Capital Investment Management LP 2.762 %	625,000	2.762 %	268 125 $
Shay Capital LLC 1.768 %	400,000	1.768 %	171 600 $
Sio Capital Management LLC 1.123 %	254,150	1.123 %	109 030 $
Schonfeld Strategic Advisors LLC 0.6514 %	147,400	0.6514 %	63 235 $
Renaissance Technologies LLC 0.5414 %	122,505	0.5414 %	52 555 $
Citadel Securities GP LLC 0.4269 %	96,604	0.4269 %	41 443 $
Adar1 Capital Management LLC 0.2625 %	59,393	0.2625 %	25 480 $
FNY Investment Advisers LLC 0.2064 %	46,700	0.2064 %	20 034 $
Millennium Management LLC 0.1752 %	39,641	0.1752 %	17 006 $

Name	Equities	%	Valuation
K2 Healthventures Equity Trust LLC 3.232 %	11,235,955	3.232 %	964 045 $
Carl Firth 1.006 %	3,495,836	1.006 %	299 943 $
The Lind Partners LLC 0.3596 %	1,250,000	0.3596 %	107 250 $
Andrew Howden 0.3047 %	1,059,315	0.3047 %	90 889 $
Robert Hoffman 0.0432 %	150,000	0.0432 %	12 870 $
Ben Goodger 0.0380 %	132,000	0.0380 %	11 326 $
Kiran Asarpota 0.0333 %	115,871	0.0333 %	9 942 $
Stephen Doyle 0.0178 %	61,980	0.0178 %	5 318 $
Tang Capital Management LLC 0.000001 %	5	0.000001 %	0 $
Neil Graham 0.000000 %	0	0.000000 %	- $

Aslan Pharmaceuticals Ltd.

3 Temasek Avenue 18 Level Centennial Tower

039190, Singapore

http://www.aslanpharma.com

address ASLAN Pharmaceuticals Limited(ASLN)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.248 USD

Average target price

76 USD

Spread / Average Target

+3,280.78%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ASLAN PHARMACEUTICALS LIMITED	-43.02%	50.87M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs